Nature Cancer, Published online: 20 May 2026; doi:10.1038/s43018-026-01168-5Castro-Dopico et al. report the design of reagents to bridge F-actin and Fcγ receptors, endowing a range of antigen-presenting cells with the ability to cross-present antigens from dead tumor cells and boosting antitumor immunity in preclinical models.